ARNI.US Arno Therapeutics
- Market cap
- USD 4.93K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2016.
Is ARNI.US undervalued?
Graham numberThe Graham number of Arno Therapeutics cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Arno Therapeutics fundamental analysis
No fundamental analysis for Arno Therapeutics yet.
Arno Therapeutics stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Arno Therapeutics
Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of …
Full company profileArno Therapeutics financial statements
2016 annualized: Fiscal year 2016 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2016, the balance sheet is the latest quarter. Figures change when the annual report is published.
Arno Therapeutics annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2012 | 2013 | 2014 | 2015 | 2016 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -10.8M | -16.9M | -21.1M | -13.4M | -11.2M |
| Net Income | -14.4M | -39.7M | 7.77M | -11.5M | -12.9M |
| Balance Sheet | |||||
| Total Assets | 12.9M | 26.9M | 8.25M | 361K | 2.36M |
| Total Liabilities | 24.3M | 39.4M | 5.29M | 8.99M | 8.07M |
| Shareholders' Equity | -11.4M | -12.5M | 2.96M | -8.62M | -5.71M |
| Cash & Short-term Investments | 10.9M | 26.8M | 7.95M | 67.0K | 2.12M |
| Cash Flow | |||||
| Operating Cash Flow | -9.42M | -14.2M | -18.8M | -9.97M | -7.30M |
| Capital Expenditure | 20.1K | 20.1K | 20.1K | 0.00 | 0.00 |
| Ratios | |||||
| ROE | - | - | 262.6% | - | - |
| ROA | -111.6% | -147.5% | 94.2% | -3,185.7% | -549.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Arno Therapeutics dividends
Arno Therapeutics has not paid dividends in the last 4 fiscal years.
Last stock split: 1:8 on Oct 30, 2013.
Who owns Arno Therapeutics
- Insiders 0.00%
- Institutions 2.68%
- Public & others 97.32%
- Shares outstanding 49.3M
- Free float 15.0M
Arno Therapeutics company profile
- Company name
- Arno Therapeutics
- Ticker
- ARNI.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Fiscal year end
- December
- Address
- 200 Route 31 North, Flemington, NJ, United States, 08822
- Phone
- 862 703 7170
- Website
- arnothera.com
About Arno Therapeutics
Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of AR-12, an orally available cancer treatment, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies, as well as in Pre-clinical studies for the treatment of various anti-microbial targets. In addition, the company's product development pipeline comprises AR-42, a novel orally available cancer therapy that is in Phase I investigator-initiated clinical study for the treatment of hematological malignancies and solid tumors. The company has license agreements with Invivis Pharmaceuticals, Inc.; the Regents of the University of Minnesota; and the Ohio State University Innovation Foundation, as well as a co-development agreement with Leica Biosystems Newcastle Ltd. Arno Therapeutics, Inc. was founded in 2005 and is based in Flemington, New Jersey.
Arno Therapeutics management
1- Mr. David M. Tanen J.D.Sec. · born 1971